|Bid||9.15 x 100|
|Ask||12.75 x 100|
|Day's Range||9.93 - 10.15|
|52 Week Range||3.21 - 10.77|
|PE Ratio (TTM)||-9.95|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
In 2Q17, Evomela reported revenues of ~$10.1 million, which is the highest quarterly revenue figure reported by the drug since its commercial launch in 2016.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Spectrum Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to SPPI-US. Comparing the performance and risk of Spectrum Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Spectrum Pharmaceuticals, Inc. (SPPI) initiated the registrational phase III study of qapzola in patients with non-muscle invasive bladder cancer (NMIBC) as per the FDA's requirement.